Why Some Arteries Clog Fast and Standard Risk Scores Miss It

Standard cardiovascular risk calculators can miss people whose arteries are aging faster than their age, sex, and cholesterol suggest. This review defines accelerated atherosclerosis (AA) as plaque that develops earlier, progresses faster, and causes more events than baseline models predict. In practice that means under-predicted by standard tools. One imaging definition of rapid progression is a rise in percent atheroma volume above 1% per year. The authors stress that inflammation amplifies, but does not replace, the causal role of apoB-containing lipoproteins.

This is a narrative review, not a new trial. It surveys conditions with firmly established AA: rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, chronic kidney disease, HIV, diabetes, and psoriasis. It also covers cardiac allograft vasculopathy and post-COVID-19 observations. The authors then examine genetic contributors (familial hypercholesterolemia, lipoprotein(a), CHIP, polygenic scores, epigenetics), imaging methods, and therapies.

The cited data are striking. In lupus, coronary event risk in women aged 35–44 has been reported at up to fiftyfold background, and antiphospholipid antibodies and cumulative steroid dose independently predicted subclinical progression. About half of antiphospholipid syndrome patients developed a new plaque over 7 years. In chronic kidney disease, coronary calcium progression of 50 or more Agatston units per year predicted events and death. REPRIEVE suggested statin benefit in HIV exceeds what LDL lowering alone explains. High Lp(a) (≥75 mg/dL) carried a hazard ratio of 1.75 for events, and guidance now suggests measuring it once in every adult. TET2 and JAK2 CHIP promote plaque through NLRP3 inflammasome and IL-1β/IL-6 signaling, and TET2 carriers benefited more from IL-1β blockade in a CANTOS analysis.

For detection, the authors favor carotid and femoral ultrasound and coronary calcium scoring. Among 1569 adults without known disease, subclinical plaque was found in 54.7%, and three or more plaques carried a hazard ratio of 2.90. Serial CT angiography can quantify progression (for example, total atheroma volume up by more than 10–20 mm³ per year). It is not recommended as routine scheduled monitoring, because of radiation, contrast, and cost. Invasive angiography is reserved for established indications, and invasive surveillance is specific to heart transplant. Intravascular ultrasound trials show high-intensity statins halted progression in about two-thirds of patients, with further regression when ezetimibe or PCSK9 inhibitors are added.

Caveats are substantial. Most evidence is observational, many imaging trials enrolled conventional coronary disease rather than AA-defined patients, and there is no universal AA definition. Pericoronary fat attenuation, microRNAs, polygenic scores, and epigenetic markers remain investigational and support risk refinement, not an AA-specific diagnosis.